Humacyte is trading 12.06% up at $0.40 after its October 15 commercial update reported a 44% increase in hospitals ordering Symvess. - Ordering hospitals rose from 34 at the end of Q2 to 49 by September 30, with new hospital ordering activity increasing each month during Q3. - The company said it could exceed its year-end goal of adding 20 hospitals. - The Phase 3 V012 presentation announcement was issued October 12; the supplied price context includes no volume figure.